Insulin Regulation of Lipolysis and Lipolysis Proteins
Study Description
“Insulin Regulation of Lipolysis and Lipolysis Proteins”
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
Location
Methods
Pharmaceutical medication involved
Patients and healthy individuals accepted
Behavioral - Immediate weight loss
Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
Drug - Pioglitazone
Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
Behavioral - Deferred weight loss
Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
Drug - Placebo
Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
Additional Information
Official Study Title
Insulin Regulation of Lipolysis and Lipolysis Proteins
Clinical Trial ID
NCT03866408
ParticipAid ID
bqxoDa
